Can we alter neonatal gut microbiome to prevent spondyloarthritis?
Dr Chao discusses Abstract 0868 at the ACR22 Convergence meeting.
Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
JAK vs TNF inhibitor Infections in RA
Dr. David Liew discusses abstract 0302 at ACR22 Convergence.
Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
Opioid and Neuropathic Use After Initiating btsDMARDs in RA
Dr. Julian Segan discusses Abstract 0925 at the ACR22 Convergence meeting.
The Dietary Intervention in PsA (DIPSA) StudyDr. Patricia Harkins talks with Professor Lihi Eder about abstract 1007 at the ACR22 Convergence meeting.
Abstract 1007: Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study
Treatment Considerations in Axial Spondyloarthritis
Dr. Lianne Gensler discusses treatment considerations in Axial SpA.
Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS
Abstract 0388: Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States
Abstract 0544: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
Abstract 0545: Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK)
What lifestyle factors affect TNF inhibitor efficacy in AxSpA?
Dr Chao discusses Abstract 1510 at ACR22 Convergence.
Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
Predicting Palindromic Prognosis
A Step Closer to Identifying Phenotypes of RA ILD
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
Giant Cell Arteritis and Polymyalgia Rheumatica Update
JAK Inhibitors for New Indications
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
JAK Inhibitors for New Indications
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Treat to Target Outcomes in Early AxSpA
Does Telemonitoring in SpA Work?
PsA Treatment: is Earlier Better?
JAK Inhibitors for New Indications
Transition from Psoriasis to PsA: Can we Prevent It?
EULAR 2024 Daily Recap - Days 1 & 2
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Voclosporin and Steroids in Lupus Nephritis
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive